Skip to content
Research/Longevity Anti Aging/Niagen (Nicotinamide Riboside)

Niagen (Nicotinamide Riboside)

NAD+ precursor that converts to NMN then NAD+. Clinically shown to increase NAD+ levels by ~60% in humans. Reduces arterial stiffness, neuroprotective. Brand name: Tru Niagen.

Intelligence Profile

Safety Profile

The safety evidence for Niagen (Nicotinamide Riboside) is limited, with most data coming from small clinical trials rather than large-scale safety studies. Evidence for comprehensive safety assessment is thin.

Known Side Effects

Based on available clinical trial data, nicotinamide riboside appears to be generally well-tolerated in healthy adults when used short-term. However, specific side effect profiles from the completed trials listed are not detailed in the provided evidence. The trials include studies in systolic heart failure patients, metabolic health, exercise supplementation, and mitochondrial biogenesis, but safety outcomes are not specified in the available data.

Contraindications

No specific contraindications are established in the provided evidence. Given the limited safety data, contraindications have not been well-characterized through clinical research.

Drug Interactions

No drug interaction data is provided in the available evidence. This represents a significant knowledge gap, as NAD+ metabolism could theoretically interact with various medications, but specific interactions have not been systematically studied or reported in the available literature.

Populations That Should Avoid Use

The evidence does not provide specific guidance on populations who should avoid nicotinamide riboside. However, given the limited safety data:

  • Pregnant and breastfeeding women should exercise caution due to lack of safety data in these populations
  • Children and adolescents - no safety data available for pediatric use
  • Patients with serious medical conditions - while one trial studied heart failure patients, broader safety in various disease states is not established

Evidence Limitations

The safety profile is based primarily on small clinical trials with limited follow-up periods. Long-term safety data is notably absent. The current evidence does not provide comprehensive information about:

  • Dose-dependent adverse effects
  • Long-term safety outcomes
  • Safety in special populations
  • Potential drug interactions
  • Serious adverse events

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before starting any new supplement, especially if you have underlying health conditions or take other medications.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.